A5017974753- Thyroid Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- Renal and related cancers
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- S100 Proteins and Annexins
- Ferroptosis and cancer prognosis
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Inflammatory mediators and NSAID effects
- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- TGF-β signaling in diseases
- Pharmacogenetics and Drug Metabolism
- Economic and Financial Impacts of Cancer
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Breast Cancer Treatment Studies
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
Eisai (United States)
2019-2023
Eisai (Japan)
2022-2023
Kunming Medical University
2018-2023
Peking University
2019-2022
Peking University First Hospital
2019-2022
National Institutes of Health
2011-2015
National Cancer Institute
2011-2015
The University of Texas MD Anderson Cancer Center
2009
The loss of antigenicity in archival formalin-fixed paraffin-embedded (FFPE) tissue sections negatively affects both diagnostic histopathology and advanced molecular studies. mechanisms underlying FFPE tissues remain unclear. authors hypothesize that water is a crucial contributor to protein degradation decrement immunoreactivity tissues. To test their hypothesis, they examined fixation time, processing humidity storage environment on integrity by immunohistochemistry, Western blotting,...
Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a poor prognosis and unmet need for effective treatment, especially patients without BRAF mutations or NTRK RET fusions. Lenvatinib US Food Drug Administration-approved radioiodine-refractory differentiated has previously demonstrated activity in small study of ATC (n = 17). We aimed to further evaluate lenvatinib ATC.This open-label, multicenter, international, phase II enrolled ATC, who had ≥ 1 measurable target...
Non-clear cell renal carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with everolimus (an mTOR is approved the treatment advanced after one prior antiangiogenic therapy.To determine safety and efficacy lenvatinib plus as a first-line patients nccRCC.This open-label, single-arm, multicenter, phase 2 study enrolled unresectable or metastatic nccRCC no anticancer therapy disease.Lenvatinib (18 mg) (5 orally once daily.The...
Abstract Background Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) at starting dose of 24 mg/day. This study explored, in double-blinded fashion, whether 18 mg/day would provide comparable efficacy with reduced toxicity. Methods Patients RR-DTC were randomized lenvatinib or The primary endpoint was objective response rate as week (ORRwk24); the odds ratio noninferiority margin 0.4. safety frequency grade ≥3...
The bottleneck arising from castration-resistant prostate cancer (CRPC) treatment is its high metastasis potential and antiandrogen drug resistance, which severely affects survival time of (PCa) patients. Secreted phosphoprotein 1 (SPP1) a cardinal mediator tumor-associated inflammation facilitates metastasis. In our previous study, we firstly revealed SPP1 was hub signature for predicting metastatic CRPC (mCRPC) development. Herein, integrated multiple databases to explore the association...
Abstract Background Head and neck squamous cell carcinoma (HNSCC) still remains a lethal malignancy benefiting from the identification of new target for early detection and/or development therapeutic regimens based on better understanding biological mechanism treatment. The overexpression Her2 Her3 receptors have been identified in various solid tumors, but its prognostic relevance HNSCC controversial. Methods Three hundred eighty-seven primary HNSCCs, 20 matching metasis 17 recurrent HNSCCs...
Radioiodine-refractory differentiated thyroid cancer (RR-DTC) has a low 10-year patient-survival rate and is challenging to treat. Lenvatinib multikinase inhibitor approved for the treatment of RR-DTC. This study aims assess Eastern Cooperative Oncology Group performance status (ECOG PS) neutrophil-to-lymphocyte ratio (NLR) as prognostic markers patients with RR-DTC treated lenvatinib.
[18F]fluoro‑2‑deoxyglucose (FDG) positron emission tomography (PET)‑computed (CT) is a functional imaging modality based on glucose metabolism. The association between the maximum standardized uptake value (SUVmax) from 18F‑FDG PET‑CT scanning and epidermal growth factor receptor (EGFR) mutation status has, to best of our knowledge, not previously been fully elucidated, potential mechanisms by which EGFR mutations alter FDG are largely unknown. A total 157 patients who were pathologically...
Pancreatic cancer is one of the most malignant gastrointestinal tumors, and it great significance to explore molecular mechanism its progression find new biological therapeutic targets. CIRBP a cold-induced protein that plays key role in many physiological pathological processes, but pancreatic still unclear. The expression tissues was slightly lower than normal tissues, high beneficial survival. At same time, immunohistochemical detection showed level cytoplasm significantly adjacent...
Background: Ticagrelor belongs to a new class of P2Y12 receptor inhibitor that has been widely used for antiplatelet therapy. This study aimed explore the effect single nucleotide polymorphisms (SNPs) in metabolic enzymes, transporters, and other relevant variants on pharmacokinetics (PK) ticagrelor its active metabolite, AR-C124910XX. Methods: The population comprised 68 healthy Chinese volunteers who were enrolled bioequivalence clinical trial. PK profile was evaluated after orally...
Prior pooled analysis of eribulin studies (301 and 305) indicated prolonged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardless visceral or nonvisceral disease. This hypothesis-generating post hoc examined the efficacy according to location metastatic sites at baseline 1864 pretreated advanced/MBC from 301 305. Analyses included OS, progression-free (PFS), objective response rate; OS PFS were also analyzed estrogen-receptor status. Eribulin...
The aim of this study was to evaluate the relationship between polymorphisms in CYP2C19 and single-dose pharmacokinetics (PKs) omeprazole healthy Chinese volunteers. A 20 mg single dose (Losec) enteric-coated capsules or tablets orally administered 656 subjects from eight subcenters. polymorphic alleles CYP2C19*2, *3, *17 were determined by Sanger sequencing Agena mass array. Plasma concentrations high-performance liquid-chromatography tandem spectrometry. PK parameters area under...
The differential diagnosis of benign and malignant effusion is often hampered by low cell content or insufficiently preserved tumor cells. In this study, we evaluated the combined diagnostic value six markers measured well-based reverse-phase protein array (RPPA) for effusion. A total 114 patients (46 with effusions, 32 probable 36 effusions) were enrolled. Expressional levels MUC1, EMA, Pan-CK, HSP90, TGF-β CA125 determined RPPA. Median relative expression Pan-CK EMA significantly higher in...
Abstract Background Lenvatinib plus pembrolizumab showed significantly improved progression-free and overall survival outcomes compared with sunitinib in patients advanced renal cell carcinoma the CLEAR study (NCT02811861). Here, we used data to characterize common adverse reactions (ARs; adverse-event preferred terms grouped accordance regulatory authority review) associated lenvatinib review management strategies for select ARs. Materials Methods Safety from 352 who received were analyzed....
6081 Background: In SELECT, lenvatinib significantly improved progression-free survival (PFS) of pts with RR-DTC versus placebo (18.3 v 3.6 months; hazard ratio [HR]: 0.21 [99% CI: 0.14, 0.31]; P<0.001). Here we examine the treatment in relation to tumor size (sum all targeted lesions) and ECOG PS. Methods: this post hoc analysis SELECT randomized receive lenvatinib, Kaplan-Meier estimates time PS ≥2 were calculated for subgroups according baseline or size. Objective response rate (ORR)...
Patients with human epidermal growth factor receptor-2-negative metastatic breast cancer (MBC), whose disease progressed on prior chemotherapy, have a poor prognosis. Eribulin, microtubule dynamics inhibitor, extends overall survival in previously treated MBC. The most common adverse event associated eribulin is neutropenia, which may result dose interruptions or reductions. A modified biweekly dosing schedule of was assessed for efficacy as well improvements hematologic toxicity.In this...
Purpose: To evaluate the possible roles of miR-34a expression in thyroid lesions, to unravel correlation between fluorodeoxyglucose (FDG) uptake and moreover, discover underlying mechanisms by which regulates FDG avidity. Methods: We retrospectively reviewed 75 patients with pathology-confirmed diseases who underwent 18 F-FDG positron emission tomography/computed tomography (PET/CT) within 3 months before undergoing surgery analysis from June 2012 July 2017. lesions was also analyzed...
In the phase 2 double-blind Study 211, a starting dose of lenvatinib 18 mg/day was compared with approved 24 in patients radioiodine-refractory differentiated thyroid cancer (RR-DTC). Predefined criteria for noninferiority efficacy mg arm were not met; safety similar both arms. Impact treatment on health-related quality-of-life (HRQoL) secondary endpoint 211.Patients RR-DTC randomly assigned to blinded or mg/day. HRQoL assessed at baseline, every 8 weeks until Week 24, then 16 weeks, and...